natgillin/translations-raw huggingface dataset:
At steady-state, the exposure ratio for the two diastereomers is approximately 2:1, with the predominant diastereomer being pharmacologically active. 
U stanju dinamičke ravnoteže, omjer izloženosti za dva dijastereoizomera iznosi oko 2:1, s tim da je farmakološki aktivan onaj dijastereoizomer koji
Do not take Victrelis if any of the above apply to you. 
Nemojte uzimati Victrelis ako se nešto od navedenog odnosi na Vas.
Boceprevir/metabolites are excreted in rat milk (see section 5.3). 
Boceprevir/metaboliti izlučuju se u mlijeko štakorica (vidjeti dio 5.3).
No clinically significant differences in pharmacokinetic parameters were observed between patients with end-stage renal disease (ESRD) and healthy subjects. 
Nisu opažene klinički značajne razlike u farmakokinetičkim parametrima između bolesnika s krajnjim stadijem bubrežne bolesti i zdravih ispitanika.
If serum haemoglobin concentrations continued to decrease to ≤ 8.5 g/dL, subjects could be treated with additional anaemia interventions, including the use of erythropoietin or ribavirin dose reduction. 
Ako su ispitanicima koncentracije hemoglobina u serumu nastavile padati do ≤ 8,5 g/dl, moglo ih se liječiti dodatnim interventnim terapijama za anemiju, uključujući primjenu eritropoetina ili snižavanje
• immunosuppressants - tacrolimus, sirolimus, cyclosporine 
• imunosupresive - takrolimus, sirolimus, ciklosporin
• hormonal replacement therapy - oestrogen-based medicines 
• hormonsku nadomjesnu terapiju - lijekove na bazi estrogena
Ribavirin dose reduction is the preferred strategy for managing treatment-emergent anaemia (see section 5.1). 
Snižavanje doze ribavirina je strategija kojoj se daje prednost u liječenju anemije koja se javlja pri liječenju (vidjeti dio 5.1).
Potent CYP3A4 inducers 
Snažni induktori CYP3A4
Combined use with peginterferon alfa-2a as compared to alfa-2b: 
Kombinacija s peginterferonom alfa-2a u usporedbi s alfa-2b:
ORAL CONTRACEPTIVES Drospirenone/Ethinyl estradiol*: (drospirenone 
Drospirenon/etinilestradiol*: (drospirenon
Victrelis contains the active ingredient boceprevir which helps to fight against hepatitis C infection by stopping the virus multiplying. 
Victrelis sadrži djelatnu tvar boceprevir koja pomaže u liječenju hepatitisa C tako što zaustavlja umnožavanje virusa.
Boceprevir was absorbed following oral administration with a median Tmax of 2 hours. 
Boceprevir se apsorbira nakon peroralne primjene uz medijan Tmax od 2 sata.
Caution should be exercised with medicines known to prolong QT interval such as amiodarone, quinidine, methadone, pentamidine and some neuroleptics. 
Potreban je oprez kod primjene lijekova koji produljuju QT-interval, kao što su amiodaron, kinidin, metadon, pentamidin i neki neuroleptici
In medicine interaction trials conducted with AKR inhibitors diflunisal and ibuprofen, boceprevir exposure did not increase to a clinically significant extent. 
U ispitivanjima interakcija lijekova provedenima s inhibitorima AKR-a diflunisalom i ibuprofenom, izloženost bocepreviru nije se povećala do klinički značajne razine.
Do not take Victrelis if you are taking any of the medicines above. 
Nemojte uzimati Victrelis ako uzimate neki od navedenih lijekova.
This is not observed in mice 
Ovo nije opaženo u miševa niti majmuna.
A study with peginterferon alfa-2a in treatment experienced patients gave consistent results as compared to the study P05101 (see section 4.4). 
Rezultati ispitivanja s peginterferonom alfa-2a u bolesnika koji su prethodno bili liječeni bili su konzistentni u usporedbi s ispitivanjem P05101 (vidjeti dio 4.4).
Close clinical monitoring is warranted. 
Neophodan je poman klinički nadzor.
Peelable blisters containing 12 hard capsules (3x4 capsule blister strip). 
Blisteri koji se odljepljuju sadrže 12 tvrdih kapsula (blister kartice sa 3x4 kapsule).
Mean age of subjects randomized was 52.7 years. 
Srednja dob randomiziranih ispitanika bila je 52,7 godina.
Injection-site reactions have not been included since Victrelis is administered orally. 
Reakcije na mjestu injekcije nisu uključene jer se Victrelis primjenjuje peroralno.
The V55I and D168N single substitutions did not reduce sensitivity to boceprevir. 
Pojedinačne supstitucije V55I i D168N nisu smanjile osjetljivost na boceprevir.
For data regarding drug-drug interactions with antiretroviral agents, see section 4.5. 
Za podatke o interakcijama s antiretrovirusnim lijekovima vidjeti dio 4.5.
A clinical drug interaction study with digoxin demonstrated that boceprevir is a mild P-gp inhibitor in vivo, increasing digoxin exposure by 19%. 
Kliničko ispitivanje interakcija lijekova s digoksinom pokazalo je da je boceprevir blag inhibitor P-gp-a in vivo te da povećava izloženost digoksinu za 19%.
• The other ingredients are sodium lauryl sulfate, microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, pre-gelatinized starch, magnesium stearate, yellow iron oxide (E172), red iron oxide (E172), titanium dioxide (E171), gelatin, and shellac. 
• Drugi sastojci su: natrijev laurilsulfat, mikrokristalična celuloza, laktoza hidrat, umrežena karmelozanatrij, prethodno geliran škrob, magnezijev stearat, željezov oksid, žuti (E172), željezov oksid, crveni (E172), titanijev dioksid (E171), želatina i šelak.
In rats, boceprevir induced reversible effects on fertility and early embryonic development in female rats at exposures 1.2-fold the human exposure at the recommended therapeutic dose. 
U štakora je boceprevir uzrokovao reverzibilne učinke na plodnost i rani embrionalni razvoj pri izloženosti ženki 1,2 puta većoj od izloženosti u ljudi pri preporučenim terapijskim dozama.
Boceprevir has not been studied in patients with decompensated cirrhosis (see section 5.2). 
Boceprevir nije ispitivan u bolesnika s dekompenziranom cirozom (vidjeti dio 5.2).
If haemoglobin is < 10 g/dL (or < 6.2 mmol/L) management of anaemia may be warranted (see 
Ako je koncentracija hemoglobina < 10 g/dl (ili < 6,2 mmol/l), možda će biti potrebno liječiti anemiju (vidjeti dio 4.8).
The data available (see section 5.3) warrant caution in patients at risk of QT prolongation (long 
Dostupni podaci (vidjeti dio 5.3) upućuju na oprez u bolesnika s rizikom od produljenja QT-intervala (urođeni dugi QT, hipokalijemija).
Boceprevir was shown to be devoid of embryonic or teratogenic potential in both rats and rabbits at maternotoxic dose levels. 
Pokazalo se da boceprevir nema embriogeni ili teratogeni potencijal ni u štakora ni u zečeva pri dozama toksičnim za majku.
Indeed, serum progesterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels indicated that ovulation was suppressed during coadministration of norethindrone 1 mg/ethinyl estradiol 0.035 mg with Victrelis (see section 4.6). 
Štoviše, razine progesterona, luteinizirajućeg hormona (LH) i folikulostimulirajućeg hormona (FSH) u serumu ukazivale su na supresiju ovulacije kod istodobne primjene noretindrona 1 mg/etinilestradiola 0,035 mg i lijeka Victrelis (vidjeti dio 4.6).
• ‘ergot' type medicines, such as dihydro-ergotamine, ergonovine, ergotamine or methylergonovine - used for migraine and cluster headaches 
• lijekove iz skupine derivata ergota, kao što su dihidroergotamin, ergonovin, ergotamin ili metilergonovin - za liječenje migrene i "cluster" glavobolja
• difficulty breathing or swallowing, wheezing, hives, itching, swelling of your face, eyes, lips, 
• otežano disanje ili gutanje, piskanje pri disanju, koprivnjaču, svrbež, oticanje lica, očiju, usana,
Heart or circulation: abnormal or rapid heart rate; heart disease caused by poor blood flow in 
Srce i cirkulacija: neuobičajeno ili vrlo brzo kucanje srca; srčana bolest uzrokovana slabim
The SVR rate was 62.5% (40/64) in subjects treated with Victrelis in combination with PR and 29.4% (10/34) in subjects treated with PR alone (see Table 6). 
Stopa SVR-a iznosila je 62,5% (40/64) u ispitanika liječenih lijekom Victrelis u kombinaciji s PR-om te 29,4% (10/34) u ispitanika liječenih samo PR-om (vidjeti Tablicu 6).
The IC50 and IC90 values for boceprevir against different genotype 1b replicons ranged from 200 to 600 nM and 400 to 900 nM, respectively, in a 72-hour cell culture assay. 
Vrijednosti IC50 boceprevira protiv različitih replikona genotipa 1b kretale su se u rasponu od 200 do 600 nM, a vrijednosti IC90 od 400 do 900 nM, u 72-satnom testu na kulturi stanica.
Caution should be exercised when boceprevir is combined with ketoconazole or azole antifungals (itraconazole, posaconazole, voriconazole). 
Potreban je oprez kad se boceprevir kombinira s ketokonazolom ili azolnim antimikoticima (itrakonazolom, posakonazolom, vorikonazolom).
Patients receiving digoxin should be monitored appropriately. 
Bolesnike koji primaju digoksin treba nadzirati na odgovarajući način.
Tachycardia*, arrhythmia, cardiovascular disorder 
tahikardija*, aritmija, kardiovaskularni poremećaj
No gender-related pharmacokinetic differences in the phase III studies have been observed in adult patients. 
Spol U ispitivanjima faze III nisu opažene farmakokinetičke razlike s obzirom na spol u odraslih bolesnika.
The subjects included 62% (104/168) genotype 1a and 38% (63/168) genotype 1b. 
Među ispitanicima je njih 62% (104/168) bilo zaraženo virusom genotipa 1a, a njih 38% (63/168) virusom genotipa 1b.
The median time for all RAVs to become undetectable was 1.17 years for genotype 1a. 
Medijan vremena potrebnog da svi RAV-ovi postanu nemjerljivi iznosio je 1,17 godina za genotip 1a.
Population pharmacokinetic analysis of Victrelis indicated that race had no apparent effect on exposure. 
Populacijska farmakokinetička analiza lijeka Victrelis ukazala je da rasa nema vidljivog učinka na izloženost lijeku.
Sustained Virologic Response (SVR) to treatment was defined as undetectable 
Trajan virološki odgovor (SVR) na liječenje definiran je kao nemjerljiva razina
Victrelis 200 mg hard capsules 
Victrelis 200 mg tvrde kapsule
At Treatment Week 24 
U 24. tjednu liječenja
Decreases in neutrophil counts may require dose reduction of peginterferon alfa or discontinuation of therapy. 
Smanjenje broja neutrofila može zahtijevati smanjenje doze peginterferona alfa ili prekid liječenja.
Concomitant administration of Victrelis and quetiapine may increase plasma concentrations of quetiapine leading to quetiapine-related toxicity, including coma. 
Istodobna primjena lijeka Victrelis i kvetiapina može povisiti koncentracije kvetiapina u plazmi što može dovesti do toksičnosti povezane s kvetiapinom, uključujući komu.
It is not known whether boceprevir is excreted in human breast milk. 
Nije poznato izlučuje li se boceprevir u majčino mlijeko u ljudi.
This co-administration might be considered on a case by case basis if deemed necessary, in patients with suppressed HIV viral loads and with HIV viral strain without any suspected resistance to the HIV regimen. 
Istodobna primjena ovih lijekova može se razmotriti u pojedinačnim slučajevima ako se smatra neophodnom, i to u bolesnika koji imaju smanjeno virusno opterećenje HIV-om i zaraženi su sojem HIV-a koji bez ikakve sumnje nije rezistentan na režim liječenja HIV-a.
• intravenous sedatives - benzodiazepines (e.g., alprazolam, midazolam, triazolam) 
• intravenski primijenjene sedative - benzodiazepine (npr. alprazolam, midazolam, triazolam)
Male patients or their female partners must use an effective contraceptive during treatment and for 7 months after treatment has been concluded. 
Bolesnici muškog spola ili njihove partnerice moraju primjenjivati djelotvornu kontracepciju tijekom liječenja i 7 mjeseci po njegovu završetku.
IL28B rs12979860 was genotyped in 653 of 1,048 (62%) subjects in SPRINT-2 (previously untreated) and 259 of 394 (66%) subjects in RESPOND-2 (previous treatment failure) [see section 5.1 for the clinical trial descriptions]. 
Genotip varijante IL28B rs12979860 određen je u 653 od 1048 ispitanika (62%) u ispitivanju SPRINT-2 (prethodno nisu bili liječeni) te u 259 od 394 ispitanika (66%) u ispitivanju RESPOND-2 (prethodno liječenje bez odgovora) [vidjeti dio 5.1 za opise kliničkih ispitivanja].
The concomitant use of Victrelis with doxazosin or tamsulosin may increase plasma concentrations of these medicines. 
Istodobna primjena lijeka Victrelis s doksazozinom i tamsulozinom može povećati koncentracije tih lijekova u plazmi.
The median time for all RAVs to become undetectable was 1.04 years for genotype 1b. 
Medijan vremena potrebnog da svi RAV-ovi postanu nemjerljivi iznosio je 1,04 godine za genotip 1b.
The use of erythropoesis stimulating agents was associated with an increased risk of thromboembolic events including pulmonary embolism, acute myocardial infarction, cerebrovascular accident, and 
Primjena lijekova koji stimuliraju eritropoezu bila je povezana s povećanim rizikom od tromboembolijskih događaja, uključujući plućnu emboliju, akutni infarkt miokarda, cerebrovaskularni incident i duboku vensku trombozu.
Croscarmellose sodium Pre-gelatinized starch Magnesium stearate 
škrob, prethodno geliran magnezijev stearat
Subjects were randomized in a 2:1 ratio and stratified based on cirrhosis/fibrosis and baseline HCV-RNA (< 800,000 IU/mL vs. ≥ 800,000 IU/mL). 
Ispitanici su randomizirani u omjeru 2:1 i stratificirani na temelju ciroze/fibroze i početne vrijednosti HCV-RNK (< 800 000 IU/ml naspram ≥ 800 000 IU/ml).
SVR rates with “missing=failure” approach were similar to those in the table: 69.9% (174/249) for subjects randomized to receive ribavirin dose reduction; 68.5% (172/251) for subjects randomized to receive 
Stope SVR-a uz pristup "nedostaje = nije odgovorio" bile su slične onima u tablici: 69,9% (174/249) za ispitanike randomizirane za snižavanje doze ribavirina: 68,5% (172/251) za ispitanike randomizirane za primanje
The combination of boceprevir with these medicines is not recommended (see section 4.4). 
Kombinacija boceprevira s tim lijekovima se ne preporučuje (vidjeti dio 4.4).
In both studies, the addition of Victrelis to the current standard of care (peginterferon alfa and ribavirin) significantly increased sustained virologic response (SVR) rates compared to the current standard of care alone. 
U oba je ispitivanja dodavanje lijeka Victrelis današnjoj standardnoj terapiji (peginterferonu alfa i ribavirinu) značajno povećalo stope trajnog virološkog odgovora (SVR) u usporedbi s primjenom samo standardne terapije.
No clinical paediatric exposure data is available (see section 4.2). 
Nisu dostupni klinički podaci o izloženosti pedijatrijskih bolesnika (vidjeti dio 4.2).
Co-administration of Victrelis with medicines that induce or inhibit CYP3A4/5 could increase or decrease exposure to Victrelis (see section 4.4). 
Primjena lijeka Victrelis istodobno s lijekovima koji induciraju ili inhibiraju CYP3A4/5 može povećati, odnosno smanjiti izloženost lijeku Victrelis (vidjeti dio 4.4).
• antiarrhythmic medicines- amiodarone, quinidine 
• lijekove protiv aritmije - amiodaron, kinidin
Please refer to the Summary of Product Characteristics for peginterferon alfa for the contraindication in patients with decompensated liver disease. 
Molimo pročitajte Sažetak opisa svojstava lijeka za peginterferon alfa za kontraindikaciju u bolesnika s dekompenziranom bolešću jetre.
Follow-up analysis of boceprevir-treated subjects who did not achieve SVR showed that the population of wild-type virus increased and the majority of boceprevir-resistant variants became undetectable over time after the end of boceprevir treatment. 
Naknadna analiza ispitanika liječenih boceprevirom koji nisu postigli trajan virološki odgovor (SVR) pokazala je da se po završetku liječenja boceprevirom populacija virusa divljega tipa povećala i da je većina varijanti rezistentnih na boceprevir s vremenom postala nemjerljiva.
Administer peginterferon alfa and ribavirin and finish through TW 48. 
Primijenite peginterferon alfa i ribavirin i završite tijekom TL 48.
This should be discussed 
Razgovarajte o tome sa svojim
Plasma concentrations of calcium channel blockers may increase when administered with Victrelis. 
Koncentracije blokatora kalcijevih kanala u plazmi mogu se povisiti kad se primjenjuju s lijekom Victrelis.
Combined use with peginterferon alfa-2a see specific section in section 4.4. 
Za primjenu s peginterferonom alfa-2a vidjeti odgovarajući odjeljak u dijelu 4.4.
The absolute bioavailability of Victrelis has not been studied. 
Nije ispitivana apsolutna bioraspoloživost lijeka Victrelis.
Boceprevir has a mean total body clearance (CL/F) of approximately 161 l/hr. 
Srednji ukupni klirens iz organizma (CL/F) boceprevira iznosi približno 161 l/hr.
The frequency of severe or life threatening infections tends to be higher in boceprevir-containing arms than the control arm. 
Učestalost teških ili po život opasnih infekcija veća je u skupinama koje su primale boceprevir nego u kontrolnoj skupini.
• warfarin and other similar medicines called vitamin K antagonists used to thin the blood. 
• varfarin i druge slične lijekove pod nazivom antagonisti vitamina
Victrelis was associated with an additional decrease of approximately 1 g/dL in haemoglobin concentration (see section 4.4). 
Victrelis je povezan s dodatnim sniženjem koncentracije hemoglobina od približno 1 g/dl (vidjeti dio 4.4).
No dose adjustment of Victrelis is required for patients with mild, moderate or severe hepatic impairment. 
Nije potrebno prilagođavati dozu lijeka Victrelis u bolesnika s blagim, umjerenim ili teškim oštećenjem funkcije jetre.
The most frequently reported adverse reactions were fatigue, anaemia (see section 4.4), nausea, 
Najčešće prijavljene nuspojave bile su umor, anemija (vidjeti dio 4.4), mučnina, glavobolja i
The mean decreases in haemoglobin values from baseline were larger in previously treated patients compared to patients who had never received prior therapy. 
Srednje vrijednosti sniženja koncentracije hemoglobina u usporedbi s početnim vrijednostima bile su veće u bolesnika koji su prethodno bili liječeni u usporedbi s onima koji prethodno nisu bili liječeni.
For additional information on use of Victrelis in patients with advanced liver disease, see section 4.4. 
Za dodatne informacije o primjeni lijeka Victrelis u bolesnika s uznapredovalom bolešću jetre, vidjeti dio 4.4.
Treatment with Victrelis should be initiated and monitored by a physician experienced in the 
Liječenje lijekom Victrelis treba započeti i nadzirati liječnik s iskustvom u liječenju kroničnog
No human data on the effect of Victrelis on fertility are available. 
Nisu dostupni podaci o učinku lijeka Victrelis na plodnost u ljudi.
Table 10 Sustained Virologic Response (SVR) rates by IL28B rs12979860 genotype 
Tablica 10 Stope trajnog virološkog odgovora (SVR) prema genotipu IL28B rs12979860
There is no specific antidote for overdose with Victrelis. 
Nema specifičnog protulijeka za predoziranje lijekom Victrelis.
Studies in vitro indicate that boceprevir primarily undergoes metabolism through the aldoketoreductase (AKR)-mediated pathway to ketone-reduced metabolites that are inactive against HCV. 
Ispitivanja in vitro ukazuju da se boceprevir prvenstveno metabolizira putem posredovanim aldoketoreduktazom (AKR) u metabolite s reduciranim ketonima koji nisu aktivni protiv HCV-a.
• Store in a refrigerator (2C - 8C) until expiry. 
Čuvati u hladnjaku (2°C - 8°C).
Use in patients having HCV genotypes other than genotype 1 
Primjena u bolesnika s HCV infekcijom drugog genotipa osim genotipa 1
If a patient has a serious adverse reaction potentially related to peginterferon alfa and/or ribavirin, the peginterferon alfa and/or ribavirin dose should be reduced. 
Ako bolesnik ima ozbiljnu nuspojavu koja može biti povezana s peginterferonom alfa i/ili ribavirinom, treba smanjiti dozu peginterferona alfa i/ili ribavirina.
The clinical significance of the reductions in etravirine pharmacokinetic parameters and boceprevir Cmin in the setting of combination therapy with HIV antiretroviral medicines, which also affect the pharmacokinetics of etravirine and/or boceprevir, has not been directly assessed. 
Nije izravno ispitan klinički značaj smanjenja farmakokinetičkih parametara etravirina i Cmin boceprevira u uvjetima kombinirane terapije antiretrovirusnim lijekovima za liječenje HIV-a koji također utječu na farmakokinetiku etravirina i/ili boceprevira.
Ketoconazole* (ketoconazole 400 mg two times daily + 
Ketokonazol* (ketokonazol 400 mg dvaput na dan +
C-boceprevir, the most abundant circulating metabolites were a diasteriomeric mixture of ketone-reduced metabolites with a mean exposure approximately 4 fold greater than that of boceprevir. 
C-boceprevira, u cirkulaciji je najzastupljenija bila dijastereoizomerska smjesa metabolita s reduciranim ketonima, s oko 4 puta većom srednjom izloženošću od boceprevira.
Prompt evaluation and treatment of infections is recommended. 
Preporučuje se odmah procijeniti infekciju i započeti s liječenjem.
However, the combination therapy of Victrelis, peginterferon alfa and ribavirin may make you feel tired, faint, a sensation of your head spinning, changes in blood pressure, confused or difficulty seeing clearly. 
Međutim, kombinirano liječenje lijekom Victrelis, peginterferonom alfa i ribavirinom može izazvati umor, nesvjesticu, osjećaj vrtnje u glavi, promjene krvnog tlaka, zbunjenost i poteškoće s vidom.
In both treatment arms, patients with cirrhosis were at a higher risk to experience Grade 3-4 thrombocytopenia compared with non 
U obje su ispitivane skupine bolesnici s cirozom imali veći rizik da dobiju trombocitopeniju stupnja 3-4 u usporedbi s bolesnicima bez ciroze.
rilpivirine AUC ↑ 39% rilpivirine Cmax ↑ 15% rilpivirine Cmin ↑ 51% 
rilpivirin AUC ↑ 39% rilpivirin Cmax ↑ 15% rilpivirin Cmin ↑ 51%
In a genotype 1a replicon, the IC50 and IC90 values for boceprevir were 900 nM and 1,400 nM, respectively. 
U jednom replikonu genotipa 1a, vrijednost IC50 boceprevira iznosila je 900 nM, a vrijednost IC90 1400 nM.
Effects of food on oral absorption 
Učinci hrane na apsorpciju nakon peroralne primjene
Due to the combined treatment with peginterferon alfa and ribavirin, extreme care must be taken to avoid pregnancy in female patients or in female partners of male patients. 
Zbog kombiniranog liječenja peginterferonom alfa i ribavirinom neophodan je izniman oprez kako bi se izbjegla trudnoća u bolesnica ili partnerica bolesnika.
Victrelis, in combination with peginterferon alfa and ribavirin, is used for chronic hepatitis C virus infection in adults (also called HCV infection). 
Victrelis se u kombinaciji s peginterferonom alfa i ribavirinom koristi za liječenje kronične infekcije virusom hepatitisa C u odraslih osoba (naziva se i HCV infekcija).
Of 314 treatment-naïve and previously treated subjects who did not achieve SVR from Phase 2/3 studies (P03523, P03659, P05216, and P05101) in whom boceprevir-resistant variants had emerged during treatment, 73% (228/314) of subjects no longer had any RAVs detected at the boceprevir-resistance associated loci by population sequencing within 3 years post-therapy. 
Među 314 ispitanika (od kojih su neki prethodno primili liječenje, a neki ne) iz ispitivanja faze II/III (P03523, P03659, P05216 i P05101) koji nisu postigli SVR i u kojih su se tijekom liječenja pojavile varijante rezistentne na boceprevir, u njih 73% (228/314) sekvenciranjem populacije unutar 3 godine nakon liječenja više nisu otkriveni RAV-ovi na lokusima povezanima s rezistencijom na boceprevir.
Heart or circulation: heart attack; stopping breathing; blood clot in the leg or arm; decreased blood flow to parts of the brain (e.g., dizziness, double vision, or weakness on both sides of the 
Krv ili cirkulacija: srčani udar; prestanak disanja, krvni ugrušak u nozi ili ruci, smanjen dotok krvi u dijelove mozga (npr. omaglica, dvostruke slike ili slabost na obje strane tijela)
Shellac Red iron oxide (E172) 
šelak željezov oksid, crveni (E172)
Victrelis 400 mg single dose) 
Victrelis pojedinačna doza od 400 mg)
If there is no such value, the FW 12 value was carried forward. 
Ako takva vrijednost ne postoji, i dalje se uzima vrijednost iz 12. tjedna praćenja.